Atabak Mokari serves as Chief Financial Officer of the Company. Mr. Mokari has served as our Chief Financial Officer since December 2018. From July 2016 to December 2018, Mr. Mokari served as Chief Financial Officer and Vice President, Corporate Development at IRIDEX Corporation, a public medical technology company, where his responsibilities included strategic and financial planning, financial analysis, capital raising, and corporate development. Mr. Mokari served as a Director in Wells Fargo Securities’ healthcare investment banking group from September 2013 to July 2016, where he assisted client companies in strategic and financial analysis, mergers and acquisitions advisory, and equity and debt capital raises. Prior to joining Wells Fargo, he served in various positions as a healthcare investment banker at UBS Group AG, from September 2009 to July 2013, and Credit Suisse, from July 2005 to February 2009. Earlier in his career, he served as an analyst at the private equity firm Olympus Partners and at the investment banking firm Bowles Hollowell Conner & Co. Mr. Mokari earned his MBA from The Tuck School of Business at Dartmouth and a B.S. in Chemistry and Biology from Duke University.
Atabak Mokari is 43, he's been the Chief Financial Officer of Bellicum Pharmaceuticals Inc since 2018. There are 15 older and 1 younger executives at Bellicum Pharmaceuticals Inc. The oldest executive at Bellicum Pharmaceuticals Inc is Dr. Alan K. Smith Ph.D., 63, who is the Chief Scientific Officer.
Atabak's mailing address filed with the SEC is C/O CORCEPT THERAPEUTICS INCORPORATED, 101 REDWOOD SHORES PARKWAY, REDWOOD CITY, CA, 94065.
Over the last 10 years, insiders at Bellicum Pharmaceuticals Inc have traded over $18,000,835 worth of Bellicum Pharmaceuticals Inc stock and bought 249,666 units worth $2,145,232 . The most active insiders traders include Bros. Advisors Lp Baker Bro..., Bros. Advisors Lpbaker Feli..., and Jon P Stonehouse. On average, Bellicum Pharmaceuticals Inc executives and independent directors trade stock every 32 days with the average trade being worth of $2,494. The most recent stock trade was executed by James M Daly on 3 January 2023, trading 60,414 units of BLCM stock currently worth $4,516.
bellicum pharmaceuticals, located near the houston medical center, is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. we are developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (hsct) and car t cell therapy. we are dedicated to creating an exceptional work environment and are passionate about working to provide innovative new treatment options that can improve health and save lives.
Bellicum Pharmaceuticals Inc executives and other stock owners filed with the SEC include: